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Our aim was to analyze metabolite profile changes in serum associated with moderate-to-heavy con-
sumption of alcohol in young adults and to evaluate whether these changes are connected to reduced
brain gray matter volumes. These study population consisted of young adults with a 10-year history of
moderate-to-heavy alcohol consumption (n ¼ 35) and light-drinking controls (n ¼ 27). We used the
targeted liquid chromatography mass spectrometry method to measure concentrations of metabolites in
serum, and 3.0 T magnetic resonance imaging to assess brain gray matter volumes. Alterations in amino
acid and energy metabolism were observed in the moderate-to-heavy drinking young adults when
compared to the controls. After correction for multiple testing, the group of moderate-to-heavy drinking
young adults had increased serum concentrations of 1-methylhistamine (p ¼ 0.001, d ¼ 0.82) when
compared to the controls. Furthermore, concentrations of 1-methylhistamine (r ¼ 0.48, p ¼ 0.004) and
creatine (r ¼ 0.52, p ¼ 0.001) were negatively correlated with the brain gray matter volumes in the
females. Overall, our results show association between moderate-to-heavy use of alcohol and altered
metabolite profile in young adults as well as suggesting that some of these changes could be associated
with the reduced brain gray matter volume.
© 2018 Elsevier Inc. All rights reserved.Introduction
Alcohol use dramatically increases during late adolescence. In
one study, approximately one in five 12th graders (17- to 18-year-adiology, Kuopio University
70210 Kuopio, Finland. Tel.:
nen).olds) in the United States reported heavy episodic (binge) drinking
in the previous 2 weeks (Johnston, O'Malley, Miech, Bachman, &
Schulenberg, 2016). Heavy episodic drinking is suggested to be
especially detrimental to adolescent brain development. An early
onset of alcohol use is associated with increased alcohol intake
during adulthood, and has been considered one of the leading risk
factors for developing alcohol use disorder later in life (DeWit,
Adlaf, Offord, & Ogborne, 2000). Drinking during adolescence
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Teppen, & Pandey, 2016).
Neuroimaging studies have shown that heavy alcohol con-
sumption has been connected with a smaller graymatter volume in
adults (Momenan et al., 2012) as well as in adolescents (Ewing,
Sakhardande, & Blakemore, 2014; Heikkinen et al., 2017; Squeglia
& Gray, 2016). However, in pathology studies, heavy alcohol use
has not been associated with significant loss in gray matter vol-
umes but rather with white matter atrophy and focal neuronal loss
(de la Monte & Kril, 2014). At the same time, changes in amino acid
and energy metabolism, such as decreased amounts of glutamine
and citrulline, have been reported in association with alcohol
consumption (Gika & Wilson, 2014; Jaremek et al., 2013;
Lehikoinen et al., 2018; Wurtz et al., 2016). Moreover, similar
changes in metabolic processes have been reported in the brain
tissue of rodents after alcohol exposure (Meinhardt et al., 2015).
Changes in metabolic processes and in brain structure are likely
to be linked. However, to the best of our knowledge, there have
been no previous studies combining brain morphometry and
metabolic profile analysis in humans. Such information could help
us to better understand the mechanisms that underlie alcohol-
related decreases in brain gray matter volume, as well as to help
identify individuals at high risk of developing brain damage due to
alcohol consumption. In this study, we compared moderate-to-
heavy drinking and light-drinking young adults, and investigated
1) differences in metabolic profiles and 2) correlations between
metabolic profiles and gray matter volumes. Previously, we have
reported detailed descriptions of changes in brain morphometry
and cortical activity in the same subjects (Heikkinen et al., 2017;
Kaarre et al., 2018).
Materials and methods
This study formed part of the Adolescents and Alcohol study,
which is focused on Finnish adolescent health and alcohol use.
Prior to participating in the study, written informed consent was
obtained from all participants. Permission for the study was pro-
vided by the Ethics Committee of Kuopio University Hospital and
the University of Eastern Finland, the Finnish National Supervisory
Authority forWelfare and Health, and the Finnish Ministry of Social
Affairs and Health. The baseline and follow-up study settings have
been described in detail elsewhere (Kekkonen et al., 2015).
The original cohort was gathered in 2004e2005, when the
participants were aged 13e17 years (n ¼ 4127) (time point 1). All
the participants were asked to complete a questionnaire concern-
ing their family, hobbies, lifestyle, and substance use. The ques-
tionnaire included the Alcohol Use Disorders Identification Test
(AUDIT), a structured questionnaire originally designed by the
World Health Organization. In this study, we used a shortened
version of the AUDIT known as AUDIT-C containing only three
questions measuring alcohol consumption. The questions were:
“How often do you have a drink containing alcohol?”, “How many
drinks containing alcohol do you have on a typical day when you
are drinking?”, and “How often do you have six or more drinks on
one occasion?” The maximum score for each question was 4,
amounting to a maximum total score of 12. The same questionnaire
was sent for completion in 2010e2011 (n¼ 797) (time point 2). The
participants in this study were selected from this group in
2013e2015 (time point 3).
Moderate-to-heavy alcohol use was defined as an AUDIT-C score
of 4 or more in males and 3 or more in females (Reinert & Allen,
2007). The light-drinking controls had low AUDIT-C scores (i.e.,
maximum 2) at both time points, and reported no binge drinking
episodes. Alcohol users were listed in descending order based on
AUDIT-C scores firstly at time point 2 and secondly at time point 1.Participants were contacted in this descending order. Age-, gender-
and education-matched light-drinking controls were recruited in
parallel to match the moderate-to-heavy alcohol users. Exclusion
criteria were a history of a head injury requiring medical treatment,
neurological illness, severe mental disorder, metal or implanted
devices in the body contraindicating magnetic resonance imaging
(MRI), regular use of other intoxicating substances, and pregnancy.
Altogether, 40 moderate-to-heavy drinking subjects and 40
light-drinking controls were recruited. Of the 80 participants, one
moderate-to-heavy drinking participant did not complete the MRI
scanning due to technical problems, and the images of another
moderate-to-heavy drinking participant, as well as two controls,
were excluded due to congenital structural abnormalities (i.e., focal
cortical dysplasia, a large cyst, enlarged ventricles). Fourteen sub-
jects were excluded due to an unsuitable AUDIT-C score at time
point 3: 5 light-drinking control participants due to binge drinking
episodes but no regular alcohol use, 6 light-drinking controls due to
an AUDIT-C score of more than 2, and 3 moderate-to-heavy
drinkers due to an AUDIT-C score of less than the cut-off point at
one of the time points. Altogether, 35 moderate-to-heavy drinking
(20 females and 15 males) and 27 light-drinking participants (15
females and 12 males) were included in the analysis.
Psychiatric assessment
All participants were interviewed at the last time point using a
structured clinical interview for DSM-IV axis I and II psychiatric
disorders (SCID-I and SCID-II) (First, Gibbon, Spitzer, Williams, &
Benjamin, 1997; First, Spitzer, Gibbon, & Williams, 1996). The in-
terviews were conducted by specialists in adolescent psychiatry
trained to undertake SCID interviews.
Metabolic profiling analysis
Venous blood samples were obtained via venipuncture by a
trained nurse to 5-mL serum separating tubes, then left to stand for
30 min, and centrifuged at 2500  g for 10 min to separate the
serum. Serum samples were frozen at 80 C until analyzed. The
sample collection was carried out according to the routine protocol
in the accredited medical laboratory of Kuopio University Hospital.
The samples were shipped to ametabolomics unit at the Institute of
Molecular Medicine Finland (FIMM) in Helsinki, Finland, to be
analyzed. Metabolomic analysis of the samples was performed
using liquid chromatographyemass spectrometry.
Metabolomics analysis was done to determine concentration of
100 polar metabolites using LCMS. All the measured metabolites
with corresponding multiple reaction monitoring (MRM) condi-
tions were given in supplementary files published elsewhere
(Kolho, Pessia, Jaakkola, de Vos,& Velagapudi, 2017). A strict quality
control system is followed during the sample analysis. All the
samples were double randomized before samples extraction and
before injecting in to the LCMS. To ensure the reproducibility and
integrity of the method during runs, QC samples (normal pooled
human serum) were incorporated to a batch of samples and run
after every 10th experimental sample, and a blank sample was run
after every fifth run.
Details of the extraction method and instrument and analytical
conditions were described in a publication by Roman-Garcia et al.
(2014). Briefly, 10 mL of labeled internal standard mixture was
added to the 100-mL samples, and the samples were allowed to
equilibrate with the internal standards. A total of 400 mL of
extraction solvent (1% formic acid in acetonitrile) was added and
the collected supernatant was dispensed into an OstroTM 96-well
plate (Waters Corporation, Milford, Massachusetts, United States)
and then filtered by applying a vacuum at a delta pressure of
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After this, 5 mL of filtered sample extract was injected into an
Acquity UPLC system coupled to a Xevo® TQ-S triple quadrupole
mass spectrometer (Waters Corporation, Milford, Massachusetts,
United States), which was operated in both positive and negative
polarities with a polarity switching time of 20 ms for metabolite
separation and quantification. The Multiple Reaction Monitoring
(MRM) acquisition mode was selected for the quantification of
metabolites. MassLynx 4.1 software was used for data acquisition,
data handling, and instrument control. The data were processed
using TargetLynx software.
Before statistical analysis of the data, analytical results were
manually checked to ensure peak shape and integration of peak for
each metabolite for all the samples. To ensure reproducibility of the
method, concentration, retention time and peak shape of each
metabolite of QC samples were compared with the validation data.
Also, %CV of concentration of QCs sampled within the run were
calculated for each metabolite. Concentration values for each
metabolite for all the samples were also checked for below lower
limit of quantification (BLLOQ). Finally, concentration values for
each metabolite were converted to mmol/L by dividing obtained
concertation from TagetLynx software with respective molecular
weight of the metabolites for statistical analysis.
For metabolomics analysis, all the metabolite standards were
purchased from Sigma-Aldrich (St. Louis, Missouri, United States).
Internal standards were ordered from Cambridge Isotope Labora-
tory. Inc., United States. LCeMS grade solvents, 2-propanol, aceto-
nitrile, and methanol (HiPerSolv) were obtained from VWR
International (Helsinki, Finland). Analytical grade chemicals formic
acid, ammonium formate, and ammonium hydroxide were pro-
cured from Sigma-Aldrich (St. Louis, Missouri, United States).
Deionized water (18 MU cm at 25 C) used for solution preparation
was made using Milli-Q water purification system (Bamstead
EASYpure RoDi ultrapure water purification system, Thermo Sci-
entific, Ohio, United States). Whole blood from normal humans was
procured from the Finnish Red Cross blood service (Helsinki,
Finland) from which serum was prepared and aliquoted (350 mL)
into the Eppendorf tubes and stored at 80 C. These serum sam-
ples were used as QCs during metabolomics analysis.
MR image acquisition and analysis
Participants underwent 3-T MRI of the brain (Philips Achieva
3.0T TX, Philips, Netherlands). A T1-weighted 3D TFE sequence (TR
8.24 ms, TE 3.82 ms, flip angle 8, FOV 240, 190 contiguous sagittal
slices with 0.94 0.94 1.0mmvoxels) as well as T2-weighted and
FLAIR sequences were acquired. An experienced neuroradiologist
evaluated all structural images for any abnormalities.
Gray matter segments were acquired using the VBM8 toolbox
(http://www.dbm.neuro.uni-jena.de/vbm/vbm8/) in SPM8 (Well-
come Department of Imaging Neuroscience, London, England;
http://www.fil.ion.ucl.ac.uk/spm) running under Matlab R2007b
(Mathworks Inc., Natick, Massachusett, United States). The T1-
weighted images were normalized into the MRI space and
segmented into gray matter, white matter, and cerebrospinal fluid,
and modulated with non-linear components only to retain their
original volume. Finally, the segments were smoothed with an 8-
mm FWHM Gaussian kernel. The volumes of whole brain gray
matter segments were retained for statistical analyses.
Statistics
Metabolic profiling was performed using univariate and multi-
variate analysis. For univariate analysis, we calculated p-values
(Student's t test, a level ¼ 0.05) and effects sizes (Cohen's d) forcomparisons between moderate-to-heavy- and light-drinking
subjects for each measured metabolite. Principal component
analysis (PCA) was used to analyze overall variance among all the
subjects. The number of principal components needed to explain
95% of variance in the data was used to adjust the a level for
multiple testing correction in the metabolic profiling analysis
(Bonferroni's method). Furthermore, we used partial least-squares
discriminant analysis (PLS-DA) to identify the variables explaining
most of the variation between moderate-to-heavy drinking sub-
jects and light-drinking controls. For the PLS-DA, variables were
normalized by standard deviation (z score) and mean centered
before analysis. Variable importance in the projection (VIP) values
is reported for each variable. Metabolites with a VIP value above 1.5,
a d value larger than 0.5 (or smaller than0.5), and a p value below
0.05 when comparing moderate-to-heavy- and light-drinking
participants were selected for correlation analysis against the
gray matter volumes. This was done to include metabolites asso-
ciated with alcohol use and exclude metabolites associated with
gender, because metabolic profiles differ between males and fe-
males, and males, on average, tend to have larger gray matter
volumes than females. Pearson's correlation coefficient was used to
measure the strength of associations. We used SPSS (IBM Corpo-
ration, version 21) to perform univariate and correlation analyses,
SIMCA (Umetrics, version 14.0.0.1359) to perform multivariate an-
alyses, and Prism (GraphPad Software Inc., version 5.03) to create
figures.
Results
We identified 100 metabolites from the samples (Table 1).
Concentrations of several metabolites were different between
moderate-to-heavy drinking subjects and light-drinking controls.
The mean concentrations, VIP, d, and p values for all measured
metabolites are provided in Table 1. Due to the correlative nature of
metabolites in serum samples, 38 principal components were
required for explaining 95% of variance in the present metabolic
profiling data. Therefore, Bonferroni's adjustment for multiple
testing reduces the a level for t-statistics to 0.0013. Using this
adjustment in the group-wise comparison, only the increased
concentrations of 1-methylhistamine in the moderate-to-heavy
drinking subjects (p ¼ 0.0011), when compared to the controls,
can be considered a statistically significant finding in the present
analysis (Table 1).
The mean abundance and standard deviations of the metabo-
lites are separately presented for males and females in Table 1. The
observed higher concentrations of creatine and arginine in the
moderate-to-heavy drinking subjects are mainly due to elevated
concentrations in the moderate-to-heavy drinking females (Fig. 1,
Table 1) when compared to the light-drinking controls. There were
no statistically significant differences between the study groups in
body weight (controls: 73.3 ± 15.2 kg [mean ± SD]; cases:
72.4 ± 15.2; p ¼ 0.436) or BMI (controls: 23.7 ± 4.0; cases:
24.9 ± 3.8; p ¼ 0.294).
The moderate-to-heavy drinking subjects had decreased brain
gray matter volumes (675.7 ± 51.2 mL [mean ± SD]; p ¼ 0.007)
when compared to the light-drinking controls (712.3 ± 51.4 mL). A
more detailed analysis of the morphometry analysis has been
published elsewhere (Heikkinen et al., 2017). Furthermore, eight
variables with a VIP value above 1.5, a d value larger than 0.5 (or
smaller than 0.5), and a p value below 0.05 (Table 1) were chosen
for Pearson's correlation analysis between gray matter volume and
metabolite abundance in the whole participant group. For the
correlation analysis, we adjusted the a level to 0.0063 to account
for multiple testing (Bonferroni's adjustment). Significant inverse
correlations were observed between gray matter volume and both
Table 1
Metabolite concentrations (mM) in serum samples (alphabetical order)
Compound All controls All alcohol users t-test (all subjects) PLS-DA Female controls Female alcohol users t-test (female) PLS-DA Male controls Male alcohol users t-test (male) PLS-DA
Mean SD Mean SD p d VIP Mean SD Mean SD p d VIP Mean SD Mean SD p d VIP
1-Methylhistamine 0.0091 0.0023 0.0122 0.0043 0.001* 0.82 2.33 0.0093 0.0023 0.0128 0.0043 0.010 0.87 1.76 0.0088 0.0022 0.0115 0.0041 0.055 0.75 1.65
2-Aminoisobutyric acid 3.08 0.99 3.95 1.46 0.011 0.65 1.88 2.95 1.06 3.98 1.42 0.029 0.75 1.50 3.23 0.86 3.92 1.51 0.192 0.52 1.10
2-Deoxyuridine 0.671 0.270 0.682 0.224 0.868 0.04 0.45 0.586 0.253 0.664 0.248 0.383 0.31 0.61 0.777 0.253 0.705 0.184 0.420 0.33 0.71
3-Hydroxyanthranilic acid 0.084 0.039 0.097 0.051 0.263 0.29 0.98 0.081 0.044 0.103 0.062 0.266 0.39 0.90 0.087 0.031 0.090 0.030 0.821 0.09 0.34
3-OH-DL-Kynurinine 0.142 0.055 0.137 0.043 0.683 0.11 0.83 0.149 0.066 0.137 0.043 0.532 0.22 1.28 0.135 0.038 0.138 0.044 0.848 0.08 0.63
4-Pyridoxic acid 0.019 0.023 0.026 0.050 0.523 0.17 0.54 0.021 0.028 0.015 0.013 0.377 0.31 0.62 0.016 0.014 0.040 0.073 0.281 0.43 0.91
5-Hydroxyindole-3-acetic
acid
0.099 0.108 0.103 0.107 0.884 0.04 0.39 0.088 0.062 0.122 0.135 0.386 0.31 0.62 0.112 0.146 0.077 0.033 0.396 0.34 0.94
Acetoacetic acid 252.96 182.59 255.25 222.29 0.966 0.01 0.82 271.86 218.93 217.29 257.53 0.526 0.22 1.02 229.34 118.72 305.87 149.62 0.177 0.54 1.38
Acetylcarnitine 7.61 3.15 7.02 2.68 0.442 0.20 0.70 8.27 3.85 6.86 2.70 0.223 0.43 0.85 6.77 1.61 7.24 2.64 0.607 0.21 1.01
Adenine 0.0011 0.0005 0.0011 0.0005 0.668 0.11 0.39 0.0010 0.0004 0.0014 0.0006 0.063 0.64 1.30 0.0012 0.0006 0.0008 0.0003 0.106 0.64 1.33
Adenosine 0.49 0.90 0.47 0.72 0.943 0.02 0.12 0.393 0.746 0.529 0.849 0.636 0.17 0.33 0.606 1.041 0.399 0.487 0.516 0.26 0.55
Alanine 433.71 120.08 435.44 125.14 0.957 0.01 0.82 423.24 130.62 460.92 143.51 0.444 0.27 1.28 446.79 103.96 401.46 84.04 0.239 0.47 1.32
Allantoin 1.22 0.69 1.30 0.96 0.709 0.10 0.58 1.37 0.80 1.25 1.00 0.708 0.13 0.34 1.03 0.45 1.37 0.89 0.249 0.46 1.49
Aminoadipic acid 3.94 0.93 3.44 0.92 0.041 ¡0.52 1.68 3.74 0.94 3.36 1.03 0.298 0.37 1.50 4.20 0.85 3.54 0.74 0.048 0.77 1.60
AMP 0.21 0.66 0.13 0.31 0.529 0.16 0.71 0.129 0.368 0.187 0.403 0.670 0.15 0.62 0.321 0.892 0.059 0.073 0.286 0.43 0.90
Arginine 111.96 17.53 124.35 21.14 0.019 0.60 1.77 109.90 20.80 129.01 24.60 0.024 0.77 1.55 114.55 11.77 118.14 12.96 0.481 0.29 1.37
Asparagine 62.56 19.94 72.16 27.24 0.135 0.39 1.36 57.92 20.00 78.47 31.72 0.040 0.70 1.44 68.36 18.28 63.74 16.30 0.511 0.27 1.06
Aspartate 6.97 2.00 7.71 2.63 0.235 0.31 1.04 7.76 2.20 8.00 3.03 0.803 0.09 0.71 5.97 1.10 7.31 1.90 0.047 0.78 1.63
Asymmetric
dimethylarginine
1.97 0.47 1.99 0.47 0.859 0.05 0.20 1.91 0.39 2.03 0.50 0.449 0.27 0.59 2.04 0.54 1.93 0.40 0.564 0.23 0.50
Betaine 28.68 12.24 31.90 14.95 0.376 0.23 0.71 26.71 12.66 28.71 15.21 0.692 0.14 0.76 31.14 11.23 36.14 13.46 0.330 0.39 1.01
cAMP 0.010 0.005 0.010 0.004 0.948 0.02 0.75 0.010 0.004 0.009 0.004 0.517 0.23 0.51 0.010 0.006 0.011 0.003 0.602 0.21 0.45
Carnitine 34.56 6.26 35.77 7.56 0.511 0.17 0.60 33.20 6.16 35.28 7.88 0.417 0.29 0.74 36.27 5.96 36.43 7.06 0.952 0.02 0.05
Carnosine 0.302 0.045 0.315 0.050 0.280 0.28 1.18 0.294 0.048 0.306 0.044 0.474 0.25 0.52 0.312 0.037 0.328 0.054 0.393 0.34 1.05
Chenodeoxycholic acid 59.66 34.64 62.68 42.78 0.770 0.08 0.51 53.87 30.13 50.78 32.91 0.784 0.10 0.69 66.91 38.36 78.56 48.85 0.521 0.26 0.58
Choline 18.21 6.04 21.00 7.34 0.121 0.40 1.28 17.29 6.11 21.83 8.76 0.104 0.56 1.19 19.36 5.76 19.89 4.62 0.801 0.10 0.57
Citrulline 18.30 4.17 19.28 5.24 0.437 0.20 0.94 17.89 5.10 18.92 6.19 0.615 0.18 1.15 18.81 2.48 19.75 3.54 0.457 0.30 0.74
Cotinine 0.014 0.054 0.372 0.572 0.002 0.77 2.55 0.003 0.002 0.328 0.545 0.032 0.74 1.95 0.028 0.078 0.430 0.600 0.036 0.82 1.69
Creatine 35.30 18.67 59.22 36.72 0.004 0.74 2.17 39.86 20.42 79.02 35.89 0.001 1.09 2.17 29.61 14.29 32.83 14.49 0.584 0.22 0.98
Creatinine 107.08 13.19 100.74 19.29 0.155 0.37 1.10 100.57 12.52 89.78 13.06 0.023 0.78 1.67 115.22 8.74 115.36 16.35 0.979 0.01 0.12
Cystathionine 0.090 0.222 0.060 0.085 0.482 0.18 0.91 0.120 0.294 0.075 0.110 0.544 0.21 0.97 0.052 0.021 0.040 0.013 0.114 0.63 1.31
Cytidine 0.232 0.089 0.208 0.076 0.262 0.29 0.98 0.252 0.109 0.196 0.077 0.091 0.59 1.18 0.208 0.045 0.225 0.072 0.497 0.28 1.22
Cytosine 0.026 0.017 0.039 0.031 0.055 0.49 1.40 0.031 0.018 0.039 0.029 0.361 0.32 0.64 0.019 0.013 0.039 0.035 0.081 0.69 1.62
Decanoylcarnitine 0.152 0.117 0.146 0.131 0.851 0.05 0.78 0.170 0.138 0.124 0.153 0.373 0.31 1.02 0.130 0.077 0.176 0.086 0.173 0.54 1.39
Deoxycytidine 5.87 1.74 5.95 1.68 0.873 0.04 0.41 5.63 1.73 5.74 1.66 0.856 0.06 0.18 6.18 1.71 6.22 1.68 0.951 0.03 0.52
D-Glucuronic acid 0.192 0.140 0.246 0.129 0.124 0.40 1.18 0.192 0.138 0.254 0.148 0.225 0.42 1.30 0.192 0.143 0.235 0.097 0.374 0.36 0.82
Dimethylglycine 3.88 1.41 4.19 1.30 0.384 0.23 0.71 4.01 1.73 4.13 1.53 0.845 0.07 0.49 3.71 0.81 4.27 0.91 0.122 0.61 1.37
D-Ribose-5-phosphate 2.15 0.94 3.07 3.56 0.203 0.33 1.03 2.12 1.07 3.85 4.45 0.162 0.49 1.04 2.19 0.74 2.04 1.12 0.694 0.16 0.34
Folic acid 0.015 0.005 0.016 0.005 0.608 0.13 0.99 0.015 0.006 0.017 0.004 0.194 0.45 0.97 0.015 0.004 0.013 0.005 0.487 0.28 0.71
GABA 0.321 0.106 0.308 0.081 0.563 0.15 0.68 0.357 0.095 0.295 0.082 0.055 0.66 1.54 0.277 0.101 0.324 0.076 0.205 0.51 1.11
Gamma-Glutamylcysteine 0.546 0.204 0.643 0.957 0.611 0.13 0.53 0.556 0.235 0.696 1.253 0.681 0.15 0.33 0.532 0.157 0.572 0.182 0.575 0.23 0.56
Glutamine 885.78 205.95 817.70 225.11 0.233 0.31 1.19 857.07 228.58 820.18 291.51 0.696 0.14 1.57 921.68 166.75 814.39 70.10 0.040 0.80 1.67
Glutathione 0.151 0.099 0.155 0.121 0.896 0.03 0.50 0.165 0.105 0.184 0.141 0.681 0.15 0.57 0.133 0.089 0.116 0.070 0.597 0.21 0.47
Glyceraldehyde 92.42 20.12 104.87 29.92 0.072 0.46 1.58 89.98 21.73 111.93 34.09 0.042 0.70 1.54 95.48 17.41 95.45 19.62 0.998 0.00 0.89
Glycine 247.50 82.45 214.27 71.69 0.101 0.42 1.52 241.70 94.73 199.84 85.82 0.194 0.45 1.13 254.74 63.11 233.51 39.01 0.312 0.41 0.86
Glycocholic acid 0.683 0.331 0.694 0.307 0.900 0.03 0.60 0.611 0.271 0.732 0.327 0.269 0.39 0.94 0.774 0.375 0.644 0.269 0.324 0.40 0.88
Guanidinoacetic acid 1.53 0.54 1.59 0.61 0.665 0.11 0.41 1.46 0.57 1.59 0.73 0.588 0.19 0.80 1.61 0.49 1.60 0.39 0.944 0.03 0.10
Guanosine 2.01 1.57 2.18 1.78 0.690 0.10 1.04 2.11 1.81 2.43 1.59 0.585 0.19 0.68 1.88 1.19 1.85 1.96 0.961 0.02 0.05
Hexanoylcarnitine 0.039 0.036 0.038 0.028 0.878 0.04 0.59 0.046 0.046 0.035 0.033 0.459 0.26 0.79 0.031 0.012 0.041 0.019 0.140 0.59 1.36
Hippuric acid 7.68 6.60 7.43 6.22 0.883 0.04 0.34 8.06 6.45 9.02 7.40 0.701 0.14 0.36 7.20 6.75 5.32 3.08 0.364 0.37 0.76
Histidine 77.50 11.87 77.27 11.82 0.939 0.02 0.83 74.91 13.11 79.18 11.03 0.318 0.35 1.02 80.74 9.13 74.72 12.34 0.187 0.53 1.21
Homocysteine 189.67 60.54 195.75 76.19 0.739 0.09 0.79 186.80 54.12 185.00 89.32 0.947 0.02 0.53 193.26 67.55 210.09 50.50 0.483 0.28 0.69
Homogentisic acid 1.25 0.90 1.35 0.91 0.670 0.11 0.84 1.43 1.09 1.07 0.91 0.319 0.35 0.88 1.03 0.51 1.72 0.76 0.015 0.93 1.95














Hydroxyproline 8.73 16.55 8.79 7.57 0.985 0.00 0.35 5.09 4.68 9.07 8.98 0.138 0.52 1.18 13.28 23.49 8.42 5.07 0.460 0.30 0.62
Hypoxanthine 14.49 2.96 13.87 3.87 0.499 0.18 0.52 13.90 2.59 13.87 4.49 0.985 0.01 0.37 15.23 3.21 13.87 2.86 0.273 0.44 0.92
IMP 0.536 0.232 0.519 0.177 0.749 0.08 0.85 0.435 0.183 0.544 0.194 0.110 0.56 1.12 0.663 0.225 0.486 0.145 0.025 0.86 1.82
Inosine 3.85 1.60 3.96 2.37 0.829 0.06 0.73 3.72 1.63 4.23 2.20 0.461 0.26 0.92 4.01 1.54 3.60 2.54 0.642 0.19 0.40
Isobutyrylcarnitine 0.442 0.177 0.440 0.201 0.967 0.01 0.39 0.430 0.155 0.414 0.181 0.792 0.09 0.54 0.457 0.201 0.475 0.221 0.841 0.08 0.34
Isoleucine 86.03 31.84 93.04 30.07 0.386 0.23 1.02 74.64 34.06 85.30 21.78 0.282 0.38 1.23 100.26 21.60 103.37 35.93 0.802 0.10 0.88
Isovalerylcarnitine 0.189 0.075 0.199 0.067 0.616 0.13 0.77 0.165 0.077 0.196 0.068 0.231 0.42 0.88 0.220 0.060 0.202 0.064 0.489 0.28 0.60
Kynurenic acid 0.030 0.010 0.031 0.015 0.771 0.08 0.99 0.027 0.010 0.027 0.014 0.995 0.00 0.06 0.034 0.008 0.037 0.013 0.583 0.22 0.59
L-5-Hydroxytryptophan 0.034 0.014 0.037 0.014 0.344 0.25 0.82 0.034 0.012 0.039 0.015 0.317 0.35 0.69 0.034 0.016 0.036 0.012 0.797 0.10 0.41
Leucine 215.30 84.77 220.70 84.57 0.807 0.06 0.73 183.38 86.05 198.15 71.22 0.594 0.19 0.60 255.21 63.61 250.77 91.34 0.892 0.06 0.73
L-Glutamic acid 19.84 11.03 26.71 10.80 0.019 0.60 1.75 16.00 8.78 23.80 10.82 0.033 0.73 1.76 24.64 11.65 30.58 9.47 0.172 0.54 1.17
L-Kynurenine 1.37 0.26 1.36 0.23 0.858 0.05 0.44 1.35 0.26 1.36 0.22 0.906 0.04 0.14 1.41 0.25 1.37 0.24 0.707 0.15 0.41
L-Methionine 31.12 8.21 32.56 9.20 0.533 0.16 1.14 28.30 7.76 33.13 9.13 0.118 0.54 1.51 34.66 7.34 31.79 9.25 0.408 0.33 1.19
Lysine 219.93 47.31 238.42 50.82 0.155 0.37 1.28 207.10 49.62 244.42 48.46 0.038 0.71 1.54 235.98 38.66 230.42 52.76 0.771 0.12 1.03
Myoinositol 12.74 1.82 13.08 2.17 0.525 0.17 0.79 12.79 2.05 13.45 2.51 0.422 0.28 1.16 12.68 1.47 12.58 1.47 0.860 0.07 0.20
NAD 0.0048 0.0017 0.0055 0.0024 0.196 0.34 0.98 0.0049 0.0018 0.0056 0.0028 0.435 0.28 0.60 0.0046 0.0015 0.0053 0.0014 0.220 0.49 1.05
Neopterin 0.0034 0.0015 0.0035 0.0022 0.818 0.06 0.96 0.0037 0.0015 0.0039 0.0025 0.818 0.08 0.37 0.0029 0.0014 0.0029 0.0015 0.988 0.01 0.04
Niacinamide 0.161 0.112 0.176 0.104 0.601 0.14 0.57 0.166 0.140 0.169 0.109 0.933 0.03 0.60 0.156 0.059 0.185 0.097 0.388 0.35 0.81
Nicotinic acid 0.624 0.252 0.655 0.183 0.591 0.14 0.56 0.530 0.234 0.620 0.189 0.236 0.42 0.97 0.741 0.222 0.701 0.162 0.606 0.21 0.54
Normetanephrine 0.0007 0.0003 0.0007 0.0003 0.841 0.05 0.35 0.0007 0.0004 0.0007 0.0003 0.478 0.25 0.50 0.0006 0.0002 0.0007 0.0003 0.200 0.51 1.11
Octanoylcarnitine 0.113 0.105 0.111 0.110 0.951 0.02 0.66 0.131 0.131 0.097 0.131 0.473 0.25 0.90 0.090 0.047 0.129 0.067 0.113 0.63 1.48
Ornithine 54.00 13.78 55.95 15.39 0.611 0.13 0.96 51.27 15.85 54.63 16.58 0.561 0.21 1.04 57.41 9.61 57.72 13.43 0.949 0.03 0.81
Orotic acid 2.22 0.43 2.45 0.85 0.209 0.33 1.11 2.15 0.34 2.39 0.80 0.301 0.36 0.81 2.31 0.52 2.53 0.91 0.460 0.30 0.63
Pantothenic acid 0.280 0.109 0.298 0.114 0.545 0.16 0.45 0.271 0.102 0.299 0.116 0.487 0.25 0.51 0.292 0.117 0.297 0.111 0.900 0.05 0.18
Phenylalanine 64.91 12.93 69.81 12.41 0.142 0.38 1.32 62.83 13.79 70.88 10.91 0.070 0.63 1.29 67.51 11.24 68.38 14.04 0.868 0.07 1.04
Phosphoethanolamine 2.09 0.56 2.15 0.71 0.700 0.10 0.36 2.08 0.56 2.08 0.70 0.979 0.01 0.32 2.09 0.56 2.25 0.73 0.548 0.24 0.73
Proline 242.34 77.93 230.49 76.46 0.557 0.15 1.07 222.40 84.33 222.15 76.47 0.993 0.00 1.21 267.27 60.47 241.62 75.00 0.364 0.37 1.17
Propionylcarnitine 0.388 0.126 0.388 0.120 0.994 0.00 0.52 0.381 0.128 0.380 0.121 0.980 0.01 0.41 0.396 0.122 0.399 0.118 0.957 0.02 0.60
Pyridoxine 0.0023 0.0004 0.0025 0.0005 0.307 0.27 0.78 0.0023 0.0004 0.0024 0.0006 0.542 0.22 0.61 0.0024 0.0003 0.0025 0.0002 0.309 0.41 0.85
Serine 144.54 30.98 135.21 27.02 0.218 0.32 1.19 140.29 28.06 140.96 28.24 0.946 0.02 0.64 149.86 33.53 127.55 23.20 0.061 0.73 1.58
Sorbitol 46.74 51.99 63.79 86.84 0.378 0.23 1.07 66.70 62.03 59.58 93.75 0.806 0.09 0.50 21.78 12.31 69.40 76.31 0.050 0.77 1.91
Spermidine 0.162 0.040 0.154 0.065 0.588 0.14 1.12 0.157 0.046 0.137 0.073 0.379 0.31 0.72 0.168 0.030 0.176 0.045 0.610 0.21 0.49
Succinate 8.96 2.33 7.46 1.92 0.008 ¡0.67 2.01 9.24 2.37 7.62 2.18 0.050 0.68 1.63 8.60 2.22 7.24 1.48 0.078 0.69 1.46
Sucrose 0.904 0.359 0.828 0.413 0.459 0.19 0.55 0.919 0.382 0.755 0.403 0.243 0.41 0.84 0.885 0.328 0.926 0.406 0.786 0.11 0.24
Symmetric
dimethylarginine
3.60 0.89 3.38 0.68 0.299 0.27 0.83 3.58 0.77 3.25 0.63 0.191 0.46 0.95 3.62 1.02 3.56 0.70 0.864 0.07 0.15
Taurine 207.30 77.22 240.39 177.59 0.377 0.23 0.67 219.22 83.03 201.83 95.72 0.589 0.19 0.38 192.39 66.32 291.81 238.22 0.189 0.52 1.18
Taurochenodeoxycholic
acid
0.447 0.422 0.557 0.515 0.377 0.23 0.79 0.444 0.426 0.677 0.593 0.220 0.43 0.86 0.450 0.418 0.398 0.324 0.731 0.14 0.33
Taurocholic acid 0.367 0.150 0.349 0.114 0.584 0.14 0.66 0.398 0.187 0.337 0.116 0.259 0.40 0.81 0.329 0.067 0.364 0.109 0.358 0.37 1.23
Threonine 124.62 30.11 129.66 39.85 0.592 0.14 0.63 121.26 32.01 136.07 43.76 0.290 0.37 0.74 128.81 26.97 121.12 31.99 0.528 0.26 0.87
Trimethylamine-N-oxide 2.25 1.50 3.71 5.80 0.215 0.32 0.91 2.01 1.21 4.42 7.37 0.232 0.42 0.84 2.55 1.74 2.76 2.12 0.793 0.11 0.43
Tryptophan 44.16 5.94 45.16 5.76 0.510 0.17 0.93 42.88 6.53 46.68 5.28 0.074 0.62 1.31 45.75 4.64 43.15 5.74 0.231 0.48 1.06
Tyrosine 58.30 14.60 64.15 17.58 0.174 0.35 1.34 58.27 16.89 66.86 18.96 0.186 0.46 1.59 58.35 11.10 60.55 14.80 0.684 0.17 1.21
UDP-glucose 1.90 0.47 1.71 0.74 0.272 0.29 0.95 1.78 0.50 1.60 0.90 0.483 0.25 0.53 2.04 0.39 1.87 0.40 0.297 0.42 1.03
Uracil 0.260 0.187 0.244 0.200 0.747 0.08 0.65 0.276 0.226 0.213 0.232 0.440 0.27 0.86 0.241 0.118 0.285 0.135 0.396 0.34 1.31
Valine 432.47 131.67 442.31 130.02 0.773 0.08 0.67 391.89 146.32 414.33 99.11 0.603 0.18 0.55 483.19 87.26 479.62 154.63 0.946 0.03 0.74
Xanthine 1.504 0.500 1.552 0.985 0.823 0.06 0.41 1.50 0.55 1.70 1.24 0.567 0.20 0.77 1.51 0.43 1.35 0.36 0.319 0.40 0.83
Xanthosine 0.057 0.017 0.063 0.022 0.206 0.33 0.96 0.057 0.018 0.064 0.022 0.315 0.35 0.77 0.056 0.016 0.062 0.023 0.467 0.29 0.72
d, Cohen's d effect size; p, p-value; PLS-DA, partial least squares discriminant analysis; SD, standard deviation; VIP, variable importance in the projection; *, significant at the adjusted a level of 0.0013; Compounds in bold were














Fig. 1. Simplified metabolic pathway describing key findings from the metabolic profiling analysis. Moderate-to-heavy use of alcohol is associated with alterations in amino acid,
energy, and creatine metabolism in young adults. Results are presented as mean z scores with 95% confidence intervals. Metabolite concentrations in serum are shown for
moderate-to-heavy drinking and light-drinking participants (colored and white symbols, respectively), separately for females and males (circles and squares, respectively). (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
N. Heikkinen et al. / Alcohol 75 (2019) 89e9794creatine (r ¼ 0.582, p < 0.0001, Fig. 2) and 1-methylhistamine
(r ¼ 0.346, p ¼ 0.0059, Fig. 2). Considering genders separately,
these correlations were significant in females (r ¼ 0.52,
p ¼ 0.0012; and r ¼ 0.48, p ¼ 0.0038; respectively) but not in
males (r¼ 0.25, p ¼ 0.216; and r ¼0.20, p¼ 0.316, respectively).
Discussion
The present results frommetabolic profile analysis indicate that
moderate-to-heavy alcohol consumption in young adults is asso-
ciated with alterations in the amino acid and energy metabolism
(Fig. 1, Table 1), which is in agreement with previous reports from
humans (Jaremek et al., 2013; Lehikoinen et al., 2018; Wurtz et al.,
2016) and animal models (Meinhardt et al., 2015). Before adjusting
for multiple testing, elevated concentrations of 1-methylhistamine
and L-glutamic acid, as well as lower succinate concentrations, were
observed in both female and male moderate-to-heavy drinkers
when compared to the light-drinking controls, indicating that
moderate-to-heavy alcohol consumption is associated with com-
mon alterations in amino acid and energy metabolism in young
people. Elevated concentrations of arginine and creatine compared
to controls were only observed in the moderate-to-heavy drinking
females, suggesting that changes in urea and creatine metabolism
are more pronounced in females (Fig. 1). However, after adjusting
for multiple testing, only elevated 1-methylhistamine concentra-
tions remained as a statistically significant difference between the
study groups. Furthermore, inverse correlations were recorded
between brain gray matter volume and serum concentrations of 1-
methylhistamine and creatine only in females (Fig. 2).
Elevated serum 1-methylhistamine concentrations could be a
proxy for neuroinflammatory processes in the brain, which could
explain our findings of a negative correlation between 1-
methylhistamine concentrations and gray matter volume (Fig. 2).
Serum 1-methylhistamine concentrations correlate with histaminerelease in the brain, because histamine is inactivated in the brain by
histamine 1-methyltransferase (EC 2.1.1.8) and converted into 1-
methylhistamine, in contrast to peripheral organs, where oxidation
by diamino-oxidase is more common (Haas & Panula, 2003;
Lintunen et al., 2001). Therefore, the elevated concentrations of 1-
methylhistamine in the serum samples of moderate-to-heavy
drinking subjects could be due to increased histamine concentra-
tion in the brain. This is in agreement with previous reports of
elevated concentrations of both histamine and 1-methylhistamine in
post mortem samples of cirrhotic alcoholics who died in hepatic
coma and in alcohol-preferring rats (Lintunen et al., 2001; Lozeva,
Tuomisto, Tarhanen, & Butterworth, 2003). Alcohol has been found
to have direct effects on the brain histamine concentration by
modulating histamine metabolism (Zimatkin & Anichtchik, 1999).
Histamine release in the brain is part of the neuroimmune response,
which has been considered to play an important part in alcohol-
induced brain damage (Crews & Vetreno, 2014). Moreover, hista-
mine modulates the function of brain systems (e.g. dopamine and
glutamate systems) that are important for behaviors related to
alcohol consumption (e.g., impulse control) (Jin & Panula, 2005;
Volkow, Wang, Fowler, & Tomasi, 2012). In fact, antagonism of the
histamine system has been proposed as a new treatment option to
reduce alcohol consumption (Nuutinen, Vanhanen, Maki, & Panula,
2012). Overall, the present results of elevated 1-methylhistamine
concentrations in moderate-to-heavy drinking young adults could
be associated with priming of the brain toward the development of
alcohol use disorder in later life (DeWit et al., 2000).
In the present study, serum creatine concentrations were higher
in the moderate-to-heavy drinking females when compared to
controls, and creatine concentrations were inversely correlated
with the brain gray matter volume in females (Fig. 2, Table 1).
Creatine kinase uses creatine to form phosphocreatine, which is
used to form adenosine triphosphate (ATP) in organs with high
energy demands (Joncquel-Chevalier Curt, Voicu, Fontaine, & et al.,
Fig. 2. Correlations between 1-methylhistamine, creatine, and brain gray matter volume. When comparing data from all study subjects, significant correlations were observed
between gray matter volume and serum 1-methylhistamine concentrations (A), and gray matter volume and serum creatine concentrations (D). When considering genders
separately, these correlations were robust in females, as shown in B and E. In male subjects, these correlations were not significant (C and F).
N. Heikkinen et al. / Alcohol 75 (2019) 89e97 952015). Creatine is synthesized from glycine and arginine via the
synthesis of guanidinoacetate by arginineeglycine amidino-
transferase (EC:2.1.4.1), followed by methylation of guanidinoace-
tate by guanidinoacetate N-methyltransferase (EC:2.1.1.2). The
elevated concentrations of creatine could be due to the increased
synthesis and/or reduced uptake of creatine. Altered creatine syn-
thesis is supported by the notion that moderate-to-heavy drinking
females also had a trend toward higher concentrations of arginine
and lower concentrations of glycine (Fig. 1). Elevated amounts of
glutamate and creatine have previously been reported in the brains
of a heterogenic group of participants with varying alcohol use
from heavy use to diagnosed AUD in a magnetic resonance spec-
troscopy study (Yeo et al., 2013). Lower concentrations of creatine
in the brain, measuredwithmagnetic resonance spectroscopy, have
been thought to be linked to neuronal damage in patients with a
diagnosed alcohol use disorder, and it has therefore also been hy-
pothesized that an elevated concentration of creatine could be an
adaptive mechanism to alcohol consumption in recreational and
binge-drinking individuals (Tunc-Skarka, Weber-Fahr, & Ende,
2015). Our results corroborate those of Tunc-Skarka et al.'s. The
inverse correlation between serum creatine concentrations and
brain gray matter volumes in females could be due to alcohol-
induced changes in energy metabolism (Figs. 1 & 2).
Additionally, in the present study, we observed a trend of higher
concentrations of L-glutamic acid in the moderate-to-heavy
drinking young adults when compared to controls (Table 1,
Fig. 1). These results are in agreement with previous research
showing that chronic alcohol consumption is associated with
elevated glutamate concentrations in serum and cerebrospinal
fluid, and with alterations in the glutamatergic system in the brain
(Holmes, Spanagel, & Krystal, 2013; K€arkk€ainen et al., 2013;
Laukkanen et al., 2015; Lehikoinen et al., 2018). High baseline
serum glutamate concentrations have also been considered as a
possible biomarker for the efficacy of acamprosate in the treatment
of subjects with alcohol use disorder (Nam et al., 2015). Elevated
glutamate concentrations are thought to cause cell apoptosis,
swelling, and death by the mechanism of excitotoxicity (Leibowitz,Boyko, Shapira,& Zlotnik, 2012). However, in the present study, we
did not observe a significant correlation between serum glutamate
concentrations and gray matter volume (Table 1). This could be due
to the statistical power of the present analysis, which only enabled
the detection of large effects.
Reduced glutamine concentrations have been associated with
alcohol consumption (Lehikoinen et al., 2018; Würtz et al., 2016).
Furthermore, the glutamate/glutamine ratio has also been sug-
gested as the biomarker for alcohol-caused liver injury (Harada
et al., 2016). In the present study, although we did not observe a
significant difference between all moderate-to-heavy and light-
drinking young adults (p ¼ 0.233, d ¼ 0.31), we did observe a
trend toward lower concentrations in moderate-to-heavy drinking
males compared to light-drinking young adults (p ¼ 0.040,
d ¼ 0.80), but not in females (p ¼ 0.696, d ¼ 0.14; Fig. 1; Table 1).
This could be due to sex-related differences, e.g. in the concentra-
tions of gonadal steroids, as well as exposure-related issues such as
the time and amount of alcohol consumed because glutamine
concentrations appear to decrease in a relatively linear manner in
relation to the amount consumed (Würtz et al., 2016).
The trend toward lower succinate concentrations in the
moderate-to-heavy drinking participants could be due to alcohol-
induced alterations in mitochondrial function, glycolysis, and
pentose phosphate pathways (Meinhardt et al., 2015). Furthermore,
altered function of the closely related urea cycle, and arginine
metabolism in particular, have also previously been reported in
abstinent alcoholics possibly reflecting permanent liver damage
(Hasselblatt et al., 2006). Moreover, 2-aminoisobutyric acid is a
product of pyrimidine metabolism (Crumpler, Dent, Harris, &
Westall, 1951). Therefore, the trend toward elevated concentra-
tions of 2-aminoisobutyric acid in the moderate-to-heavy drinking
participants could be due to increased metabolism of pyrimidines,
possibly reflecting changes seen in the components of amino acid
and energy metabolism discussed above. Finally, aminoadipic acid
is a gliatoxic agent and can influence, for example, GABAergic
function, and could therefore influence alcohol-induced neuropa-
thology (Park, Jo, Zheng, Patel, & Stern, 2009). Interestingly, our
N. Heikkinen et al. / Alcohol 75 (2019) 89e9796laboratory detected altered GABAergic activity in the brains of the
same group of moderate-to-heavy drinking participants in an
earlier study (Kaarre et al., 2018).
In the present study, moderate-to-heavy drinking subjects had
higher concentrations of the nicotine metabolite cotinine (Table 1).
Many of the moderate-to-heavy drinking subjects (16 out of 35)
used tobacco, while only 2 of the 27 light-drinking controls used
tobacco. This is a common limitation of clinical studies on alcohol
use, since most persons with heavy alcohol consumption also use
tobacco (Kalman, Morissette, & George, 2005). Therefore, some of
the changes seen in the metabolic profiles of the moderate-to-
heavy drinking subjects could be due to the use of tobacco or the
combined effect of alcohol and tobacco use. It has been determined
in animal models that some components of tobacco smoke (e.g.,
nicotine-derived nitrosamine ketone) can influence alcohol-
induced neuropathology, especially in the white matter of pre-
frontal parts of the brain (Tong et al., 2015).
In the present study we measured metabolite concentrations
only in the periphery. This can be considered a limitation, as there is
variation between the metabolites on how well serum concentra-
tions reflect the brain concentrations. For some metabolites, these
associations are more linear. For example, 1-methylhistamine is
mainly produced in the brain, but its serum concentration has been
considered to reflect the concentration in the brain (Haas & Panula,
2003; Lintunen et al., 2001). For some other metabolites, which are
mainly produced in peripheral organs, such as creatine (Joncquel-
Chevalier Curt et al., 2015), the connection between serum and
brainmetabolite concentrations is more complex. However, even in
these cases peripheral changes in metabolite concentrations can
serve as important biomarkers. For example, there is preliminary
evidence that serum metabolite concentrations could be used to
predict acamprosate treatment outcomes although the mecha-
nisms of action are based on the central neurotransmitter affinity
(Hinton et al., 2017; Nam et al., 2015).
Other limitations of the present study include the relatively low
number of subjects for the metabolic profiling analysis. However, in
the MRI analysis, the groups were reasonably sized. In practice, this
means that we were only able to observe differences between the
moderate-to-heavy drinking subjects and light-drinking controls
with a large effects size. Because of the limited sample size, we did
not investigate correlations between alcohol use associated
changes in specific brain regions (Heikkinen et al., 2017) and
metabolite concentrations, which should be done in future studies
with larger cohorts. Moreover, the family history of the participants
was not recorded. Some of the metabolic and/or brain structural
differences could be due to hereditary factors. Although there was
no significant difference between the subjects and controls in BMI,
recording other possible co-factors such as exercise routines, sleep
patterns and stress levels of the participants would have
strengthened the results of the study. The strengths of the study
include the monitoring of alcohol consumption by the participants
during adolescence, as well as the collection of venous blood
samples following overnight fasting, thus controlling for the effects
of diet on metabolites with a rapid conversion rate. Both 1-
methylhistamine and creatine have a half-life of 3 h or less (Belic
et al., 1999; Deldicque et al., 2008).
In conclusion, the moderate-to-heavy drinking young adults,
who had also been drinking for at least 10 years during their
adolescence, had an altered metabolic profile when compared to
light-drinking controls. We observed significant inverse correlations
between brain gray matter volume and serum concentrations of 1-
methylhistamine and creatine in young females. This finding may
reflect the neurotoxic and neuromodulatory effects of alcohol on the
brain. Furthermore, moderate-to-heavy alcohol consumption ap-
pears to have a larger effect on the metabolic profiles and brain graymatter volumes of female subjects when compared tomales. Further
research is warranted to explain the mechanism and possible long-
term consequences of these metabolic and structural changes.
Future research should look into the possibility that changes in
serum metabolic profiles (in combination with measures of alcohol
consumption such as AUDIT) could be used to identify young adults
at risk of developing alcohol-induced decreases in brain gray matter.Acknowledgments
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